Bosulif Approved for Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Share this content:

Pfizer announced that the FDA has approved Bosulif (bosutinib) for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

The registrational trial (Study 200) was a global, single-arm, open-label, multi-cohort, Phase 1/2 study of >500 patients with imatinib (Gleevec; Novartis)-resistant or –intolerant Ph+ CML with separate cohorts for chronic, accelerated and blast phase disease previously treated with one prior TKI (imatinib) or more than one TKI (imatinib followed by dasatinib [Sprycel; Bristol-Myers Squibb] and/or nilotinib [Tasigna; Novartis]).

The major cytogenetic response (MCyR) at 24 weeks for patients with chronic phase CML who had been previously treated with imatinib only (n=266) was 33.8% (95% CI: 28.2, 39.9). With a minimum follow-up of 23 months, 53.4% of patients achieved a MCyR. Of patients who achieved MCyR, 52.8% had a MCyR lasting at least 18 months. The median duration of MCyR was not reached for these patients.

The MCyR by 24 weeks for patients with chronic phase CML who had been treated with imatinib and at least one other TKI (n=108) was 26.9% (95% CI: 18.8, 36.2). With a minimum follow-up of 13 months, 32.4% of patients achieved a MCyR. Of patients who achieved MCyR, 51.4% had a MCyR lasting at least nine months. The median duration of MCyR was not reached for these patients.

A low rate of transformation (4%, n=16) from the chronic phase to the advanced or blast phase was also observed in patients treated with Bosulif.

Bosulif is a kinase inhibitor that limits cancer cell growth by inhibiting the Abl and Src signaling pathways. Bosulif is expected to be available mid-September. It will be available as 100mg and 500mg tablets.

For more information, call (800) 438-1985 or visit www.pfizer.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs